icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
CqweYEmAfFmSbV54
Listen
